e-learning
resources
Stockholm 2007
Monday 17.09.2007
Drug-resistant and multidrug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical efficacy of once a day linezolid and azithromycin in the treatment of multi-drug resistant tuberculosis
S. Agarwal (Varanasi, Uttar Pradesh, India)
Source:
Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Session:
Drug-resistant and multidrug-resistant tuberculosis
Session type:
Oral Presentation
Number:
2683
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Agarwal (Varanasi, Uttar Pradesh, India). Clinical efficacy of once a day linezolid and azithromycin in the treatment of multi-drug resistant tuberculosis. Eur Respir J 2007; 30: Suppl. 51, 2683
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis
Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017
Year: 2018
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008
Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004
Surgical treatment of patients with disseminated destructive multidrug resistant lung tuberculosis
Source: Eur Respir J 2005; 26: Suppl. 49, 489s
Year: 2005
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 555s
Year: 2003
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis
Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis
Year: 2007
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT
Source: Eur Respir J 2003; 22: Suppl. 45, 526s
Year: 2003
Combination therapy of gefitinib and CYP3A4 inhibitor on non-small-cell lung cancer patients with an
EGFR
mutation and carcinomatous meningitis
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM)
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
The efficacy of treatment of patients with drug resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 661s
Year: 2007
A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer
Source: International Congress 2019 – Lung cancer?
Year: 2019
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
The efficiency of polychemotherapy with the use of PAS by the patients with chemoresistant lung tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 13s
Year: 2006
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Diaskintest at patients after successful treatment of lung tuberculosis
Source: International Congress 2017 – Migrants and screening
Year: 2017
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept